Literature DB >> 22791505

Overexpression of caveolin-3-enhanced protein synthesis rather than proteolysis inhibition in C2C12 myoblasts: relationship with myostatin activity.

Abdessattar Hadj Sassi1, Julien Monteil, Patrick Sauvant, Claude Atgié.   

Abstract

Caveolin-3 (cav-3), which is involved in the regulation of signal transduction and vesicular trafficking, could interact with activin receptor IIB to inhibit myostatin (MSTN) activity and may therefore play a role in muscle development and hypertrophy. MSTN is a member of the transforming growth factor-β family, identified as a negative regulator of skeletal muscle mass. The expression of MSTN is fiber-type specific and the greatest amount of MSTN is present in fiber, which is composed of myosin heavy chain (MHC) type IIb. MSTN acts through the activin receptor IIB to activate smad2/3 which leads to an increase in gene transcription involved in muscle atrophy. Muscle hypertrophy is a consequence of two mechanisms: (1) the inhibition of proteolysis such as the calcium-dependent proteolytic system calpains and calpastatin and (2) an increase in protein synthesis through the Akt/mTOR/p70s6K pathway. In order to determine which of the two processes predominates in inhibition of MSTN activity in a cav-3 context, we transfected a C2C12 cell line with plasmids containing mstn or cav-3 wild genes. The results reported in this study demonstrate that inhibition of MSTN activity by overexpression of cav-3 induces an activation of protein synthesis rather than an inhibition of proteolysis through the calcium proteolytic system. The inhibition of phosphorylation of smad-3 due to overexpression of cav-3 causes an increase in the phosphorylation of the ribosomal protein S6, promoting the synthesis of MHC type II, probably through activation of Akt/mTOR/p70s6K. These data highlight the role of protein synthesis as the predominant mechanism in muscle hypertrophy observed when the expression of MSTN is altered and confirm the value of studying the physiological role of MSTN in the growing processes of skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791505     DOI: 10.1007/s13105-012-0192-9

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  28 in total

Review 1.  Signalling and the control of skeletal muscle size.

Authors:  Anthony Otto; Ketan Patel
Journal:  Exp Cell Res       Date:  2010-04-18       Impact factor: 3.905

Review 2.  Cellular and molecular events controlling skeletal muscle mass in response to altered use.

Authors:  François B Favier; Henri Benoit; Damien Freyssenet
Journal:  Pflugers Arch       Date:  2008-01-12       Impact factor: 3.657

Review 3.  Signaling pathways perturbing muscle mass.

Authors:  David J Glass
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-05       Impact factor: 4.294

4.  Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.

Authors:  Yutaka Ohsawa; Hiroki Hagiwara; Masashi Nakatani; Akihiro Yasue; Keiji Moriyama; Tatsufumi Murakami; Kunihiro Tsuchida; Sumihare Noji; Yoshihide Sunada
Journal:  J Clin Invest       Date:  2006-10-12       Impact factor: 14.808

Review 5.  Myoblast models of skeletal muscle hypertrophy and atrophy.

Authors:  Adam P Sharples; Claire E Stewart
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-05       Impact factor: 4.294

Review 6.  Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass.

Authors:  Marco Cassano; Mattia Quattrocelli; Stefania Crippa; Ilaria Perini; Flavio Ronzoni; Maurilio Sampaolesi
Journal:  J Muscle Res Cell Motil       Date:  2010-03-02       Impact factor: 2.698

7.  Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.

Authors:  Anne Ulrike Trendelenburg; Angelika Meyer; Daisy Rohner; Joseph Boyle; Shinji Hatakeyama; David J Glass
Journal:  Am J Physiol Cell Physiol       Date:  2009-04-08       Impact factor: 4.249

Review 8.  Transforming growth factor-beta and myostatin signaling in skeletal muscle.

Authors:  Helen D Kollias; John C McDermott
Journal:  J Appl Physiol (1985)       Date:  2007-11-21

9.  Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle.

Authors:  Stefan Girgenrath; Kening Song; Lisa-Anne Whittemore
Journal:  Muscle Nerve       Date:  2005-01       Impact factor: 3.217

Review 10.  Signaling in muscle atrophy and hypertrophy.

Authors:  Marco Sandri
Journal:  Physiology (Bethesda)       Date:  2008-06
View more
  2 in total

1.  Caveolin-3 promotes glycometabolism, growth and proliferation in muscle cells.

Authors:  Lina Shang; Tingting Chen; Yufeng Deng; Yiyuan Huang; Yuanheng Huang; Jing Xian; Wensheng Lu; Lihui Yang; Qin Huang
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

2.  Effect of type 2 diabetes mellitus caveolin-3 K15N mutation on glycometabolism.

Authors:  Yiyuan Huang; Yufeng Deng; Lina Shang; Lihui Yang; Juanjuan Huang; Jing Ma; Xianshan Liao; Hui Zhou; Jing Xian; Guining Liang; Qin Huang
Journal:  Exp Ther Med       Date:  2019-08-02       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.